Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation. - Wikidata - wikimedia - TriplyDB

Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation.

Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation.

http://www.wikidata.org/entity/Q33386275

about

Multidrug resistance reversal effect of DMC derived from buds of Cleistocalyx operculatus in human hepatocellular tumor xenograft model.Tan IIA inhibits H1299 cell viability through the MDM4‑IAP3 signaling pathway.

P2860

Q33351826-8AAD6B85-BE69-4E97-BCBB-813E0C0C2632 Q47328917-549E1604-71A7-45AF-8F31-C68A208992AF

P2860

Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation.

http://www.wikidata.org/entity/Q33386275

description

2008 nî lūn-bûn

@nan

2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Tripeptide tyroserleutide plus ...... y and side effect attenuation.

@ast

Tripeptide tyroserleutide plus ...... y and side effect attenuation.

@en

type

label

Tripeptide tyroserleutide plus ...... y and side effect attenuation.

@ast

Tripeptide tyroserleutide plus ...... y and side effect attenuation.

@en

prefLabel

Tripeptide tyroserleutide plus ...... y and side effect attenuation.

@ast

Tripeptide tyroserleutide plus ...... y and side effect attenuation.

@en

P1433

Q33386275-2422D82E-8FEA-4109-B375-CBF899A86B42

P1476

Q33386275-C6FBFD08-B436-4859-9BEE-C46B72FC07CF

P2093

Q33386275-0766AAB6-94BD-46D0-BCB4-71023638DEBA

Q33386275-1F570CC7-8F37-45C9-88C6-AAFF94D6B3F5

Q33386275-30D398CD-E2FA-4DC1-BA38-0E12E52C020A

Q33386275-55B57D65-9AA2-4FDA-A01C-1098A2A417E9

Q33386275-A006B30F-5B57-4E71-9462-D637FECBF6DB

Q33386275-ACD39E08-4125-45BE-A24A-55FBEB1BF2A9

Q33386275-B9023DF6-CFB0-403F-A30A-1FABD363A989

Q33386275-BB72AB8C-9B4A-4E19-949E-F336DF4B271D

Q33386275-E865AED6-6111-4BE5-8AA6-EE3D781BD543

Q33386275-F5C63C97-85C5-4373-B0C3-49680ABECB7A

P2860

Q33386275-06697192-296D-424E-9583-2554957BA402

Q33386275-15E7D445-3A1C-4E78-8CFD-E6ED17A86E20

Q33386275-205E2E57-0B85-4CFA-A6BC-48AD2F989C00

Q33386275-2E6B9E45-F08D-4102-B81E-355FFC4024FC

Q33386275-44194AEB-8FD2-4174-AFC6-5A76C4FA989B

Q33386275-47675970-DA7A-48B2-970E-864A7DF78ECF

Q33386275-7266B934-1D9F-479D-959E-87CA8D647ACC

Q33386275-7F062002-CFC3-4E6C-B2DB-4BEF248B61E6

Q33386275-81FCCE9A-63B4-409B-A68A-6DA819F9DDE5

Q33386275-8DFE0BBE-6582-4683-BA40-3A3EA0E99D74

P2888

Q33386275-9DEB81D6-E96D-418F-91E2-051AD6A7FECB

P304

Q33386275-A41B3B7C-C38C-44A0-860E-CC697986AF2F

P31

Q33386275-01BDCBAC-4EAE-4273-B53C-A4A83AA85934

P356

Q33386275-D1E2193B-616D-4746-BE59-768ABBDCFB85

P407

Q33386275-56666DF1-57BA-423D-AB3F-F9CC4B22DEE9

P478

Q33386275-FC7CE94D-CD41-43E7-A71F-DA5D9CDD80C1

P577

Q33386275-1CA6645F-5D2F-43F5-9435-0770A21D617C

P5875

Q33386275-C2D4E3F4-F7F3-4E59-9EFF-3E83452E59DE

P6179

Q33386275-74F2757D-33EE-456F-9BF2-B8AF1D8443F0

P698

Q33386275-7B61B87E-F00D-4375-8711-B9D20DF126DA

P932

Q33386275-03BC4336-6B2A-4232-92BD-8536695600FD

P356

1471-2407-8-342

P1433

P1476

Tripeptide tyroserleutide plus ...... y and side effect attenuation.

@en

P2093

Chun-lei Zhou

http://www.w3.org/2001/XMLSchema#string

Jing Jia

http://www.w3.org/2001/XMLSchema#string

Li Wang

http://www.w3.org/2001/XMLSchema#string

Li-juan Chen

http://www.w3.org/2001/XMLSchema#string

Qiong Xu

http://www.w3.org/2001/XMLSchema#string

Rong Lu

http://www.w3.org/2001/XMLSchema#string

Song Wang

http://www.w3.org/2001/XMLSchema#string

Yu Liang

http://www.w3.org/2001/XMLSchema#string

Zhi Yao

http://www.w3.org/2001/XMLSchema#string

Zhi-feng Zhu

http://www.w3.org/2001/XMLSchema#string

P2860

Synergistic antitumor effect of TRAIL and doxorubicin on colon cancer cell line SW480.

A clinicopathologic analysis of adriamycin cardiotoxicity.

Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the Receptor and Biomarker Group of the European Organization for Research

Quality of life in patients with brain tumor: what's relevant in our quest for therapeutic efficacy.

Differential long-term subcellular responses in heart and liver to adriamycin stress. Exogenous L-carnitine cardiac and hepatic protection.

Subcellular effects of adriamycin in the heart: a concise review.

Sensitivity tests of tumors to cytostatic agents. I. Comparative investigations on transplanted tumors in vivo and in vitro.

The effect of tripeptide tyroserleutide (YSL) on animal models of hepatocarcinoma.

Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin.

Doxorubicin toxicity in perfused rat heart. Decreased cell death at low oxygen tension.

P2888

1471-2407-8-342

P304

342

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-8-342

http://www.w3.org/2001/XMLSchema#string

P407

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2008-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23489632

http://www.w3.org/2001/XMLSchema#string

P6179

1024669569

http://www.w3.org/2001/XMLSchema#string

P698

19025669

http://www.w3.org/2001/XMLSchema#string

P932

2601048

http://www.w3.org/2001/XMLSchema#string